Innovative TechnologyRani Therapeutics has developed the RaniPill capsule, which is a novel, proprietary, and patented platform technology intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral administration.
Investor ConfidenceRani Therapeutics announced pricing of a $10M share purchase agreement with a single institutional investor for the sale of 3.3M shares of Class A common stock, indicating investor confidence in the company's future.
Market ExpansionRani's pipeline in psoriasis, psoriatic arthritis, hypoparathyroidism, and obesity presents an opportunity to tap into a global biologics market that reached $516B in 2022 and is expected to grow to $856B by 2031.